This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:2228.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has licensed the first pneumococcal vaccine for use in infants and toddlers. The 7-valent, polysaccharide-protein conjugate vaccine (Prevnar, Wyeth Lederle Vaccines, Philadelphia) was approved for active immunization of infants and toddlers against invasive disease (meningitis and bacteremia) caused by Streptococcus pneumoniae. The capsular serotypes contained in the conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) cause approximately 80% of invasive disease in children under age 6 years in the United States. The routine schedule is a four-dose series of 0.5 mL beginning at age 2 months.

The efficacy of Prevnar was assessed in a prospective, double-blind clinical trial with approximately 38,000 children who were randomized (1:1) to receive Prevnar or the control vaccine (an investigational meningococcal group C conjugate vaccine [MnCC]) at 2, 4, 6, and 12 through 15 months of age. Routinely recommended vaccines were also administered. Among fully vaccinated children, 17 cases of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?